KEYTRUDA® (pembrolizumab) in combination with Inlyta® (axitinib) reduced risk of death
Merck announced full results from the pivotal Phase 3 KEYNOTE-426 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with Inlyta (axitinib), a tyrosine kinase inhibitor, for the first-line treatment of advanced renal cell carcinoma. These data were published in the NEJM. February 16, 2019